StrongNet: An International Network to Improve Diagnostics and Access to Treatment for Strongyloidiasis Control

Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis

“…7,8 Access to parenteral ivermectin and pharmacokinetic data to guide therapy is limited. 9 Serial plasma and postmortem ivermectin analysis from our patient is described.…”

Diagnosis of strongyloides stercoralis infection in immunocompromised patients: problems and perspectives / Diagnóstico da infecção por strongyloides stercoralis em pacientes imunocomprometidos: problemas e perspectivas

“…Strongyloidiasis is a parasitic disease caused by the intestinal nematode Strongyloides stercoralis, prevalent in several parts of the world, especially in tropical and subtropical regions such as Latin America. The evaluation of the human infection by Strongyloides stercoralis is not quite precise; according to some authors it is estimated that 30 to 370 million people are infected with this helminth throughout the world (1)(2)(3) .…”

Serologic Monitoring of Public Health Interventions against Strongyloides stercoralis

“…It is associated with poverty and the lack of basic services and sanitary conditions and has been recognized as one of the most neglected of the neglected tropical diseases (NTDs) (not officially listed as NTDs). [3][4][5][6] It is particularly endemic in tropical and subtropical areas like northern Argentina, where prevalence rates as high as 30-50% have been reported, with socioeconomic, and environmental conditions favorable for its transmission and persistence. [7][8][9] The particularities of the life cycle of S. stercoralis, which include an autoinfective step where L3 larvae reinfect the host through the intestinal mucosa and the perianal skin, can lead to persistent and lifelong infections, which could develop into fatal complications like hyperinfection syndrome and disseminated infection.…”

“…In this scenario, anthelminthic therapy should be curative; therefore, the evaluation of response to treatment and management of strongyloidiasis have become a major concern in strongyloidiasis, which needs to be studied and more deeply addressed. 5,[10][11][12] Nowadays, ivermectin is the treatment of choice for strongyloidiasis. Its superior efficacy compared with albendazole and its better safety profile compared with thiabendazole have been demonstrated.…”

“…Currently, ivermectin donations are limited to the control of onchocerciasis and also to programs for the control of lymphatic filariasis in areas coendemic with onchocerciasis. 5,13 The coproparasitological tests that are conventionally used to diagnose Strongyloides (direct smear, formalin ether concentration, Baermman, and agar plate culture) are not sensitive enough, particularly in chronic infections where a high percentage of the cases are not detected. 3,12,[14][15][16] Because of the problems with conventional parasitological tests, efforts have focused on the development and evaluation of novel serological techniques, but these show variable sensitivity and specificity depending on the source of antigen and the population tested.…”